The milestone payment will not impact Genmab's 2022 financial guidance provided on November 9, 2022. About Large B-cell Lymphoma (LBCL) and Diffuse Large B-cell Lymphoma (DLBCL) Large B-cell lymphoma (LBCL) is a fast-growing type of non-Hodgkin's lymphoma (NHL), a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. There are an estimated 150,000 new LBCL cases each year globally. 1,2 Diffuse large B-cell lymphoma (DLBCL) is a fast-growing type of NHL 3 and the most common type of NHL worldwide, accounting for approximately 31 percent of all NHL cases. 2 DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men. 1 About the EPCORE™ NHL-1 Trial EPCORE™ NHL-1 is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab including a phase 1 first-in-human, dose escalation part; a phase 2 expansion part; and an optimization part.